Sara Eapen
Manager
Boston
SEapen@analysisgroup.com
Education:
Ph.D. and M.A., biostatistics, University of Rochester; M.S., statistics, University of Mumbai; B.S., statistics, Saint Xavier's College
Summary of Experience:
Dr. Eapen is a biostatistician experienced in collaborative clinical research and statistical consulting within academia and industry. Her varied casework includes performing pharmacoeconomics evaluations and outcome studies; conducting study design and data analysis to support medical product marketing; developing reimbursement strategies; analyzing health care policy and regulation; and performing large database retrospective analysis, clinical trial analyses, and meta-analyses. She has consulted to law firms on a number of health care litigation cases and has coauthored several papers, posters, and abstracts covering a range of therapeutics areas. Dr. Eapen’s prior work with Novartis Pharmaceuticals Corporation and Dana-Farber Cancer Institute included the design, monitoring, and analysis of clinical trials, with particular emphasis on cancer and quality of life for terminally ill patients. She also served as a primary biostatistician for phase I trials in hypertension, rheumatoid arthritis, and cardiovascular diseases and successfully targeted two compounds for commercialization as blockbuster drugs. Her research has appeared in Clinical Cancer Research, Journal of Clinical Oncology, Neurology, Journal of Palliative Medicine, and Biometrics.